文献速递脑血管病

心房颤动缺血性卒中后启动抗凝的最佳延迟时间:实用性反应适应性随机临床试验

Optimal Delay Time to Initiate Anticoagulation After Ischemic Stroke in Atrial Fibrillation: A Pragmatic, Response-Adaptive Randomized Clinical Trial.
PubMed 文献 · JAMA Neurol · 2025-01-01

这项2期实用性反应适应性随机临床试验于2017年6月至2023年6月在德克萨斯州急性护理医院纳入200例轻中度缺血性卒中合并心房颤动患者,随机分配至卒中后第3或4天、第6天、第10天或第14天启动直接口服抗凝药。30天内复合主要结局方面,第1组无缺血事件,第2、3、4组分别有3、2、2例缺血事件;出血事件分别为1、1、1、0例。第1组为最佳启动日的后验概率为0.41,高于第2组0.26、第3组0.17、第4组0.15;未确定明确最优启动日,但证据提示前2周内较早启动优于较晚启动。

要点

  • 200例轻中度缺血性卒中合并心房颤动患者随机分配至第3或4天、第6天、第10天或第14天启动直接口服抗凝药。
  • 30天内缺血事件:第1组0例,第2组3例,第3组2例,第4组2例;出血事件:第1组1例,第2组1例,第3组1例,第4组0例。
  • 第1组为最佳启动日的后验概率0.41,第2组0.26,第3组0.17,第4组0.15;未确定明确最优启动日。

核心结论

  • 未确定心房颤动患者缺血性卒中后启动直接口服抗凝药进行二级预防的明确最优启动日,但证据提示卒中后前2周内较早启动优于较晚启动。

研究设计与样本

  • 2期实用性反应适应性随机临床试验,于2017年6月至2023年6月在德克萨斯州急性护理医院开展,纳入200例轻中度缺血性卒中(最小病灶直径1.5 cm)合并心房颤动患者,随机分配至卒中后第3或4天、第6天、第10天或第14天启动直接口服抗凝药。

主要发现

  • 30天内缺血事件:第1组0例,第2组3例,第3组2例,第4组2例;出血事件:第1组1例,第2组1例,第3组1例,第4组0例。
  • 第1组为最佳启动日的后验概率为0.41,第2组0.26,第3组0.17,第4组0.15。
  • 反应适应性随机化可行,并倾向于较早启动直接口服抗凝药的组。

关键数值与推荐

  • 临床实践指南推荐心房颤动卒中后2周内启动抗凝治疗。
  • 复合主要结局为指数卒中发病后30天内的缺血事件(卒中或系统性栓塞)或出血事件(症状性颅内出血或重大系统性出血)。

临床怎么用

  • 作者认为,尽管未确定明确最优启动日,证据提示卒中后前2周内较早启动直接口服抗凝药优于较晚启动。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Clinical practice guidelines recommend initiation of anticoagulation within 2 weeks after stroke with atrial fibrillation. It is unknown whether there is an optimal starting day within the 14-day period that balances the risks of recurrent embolic events against serious hemorrhagic events. OBJECTIVE: To determine if there is an optimal delay time to initiate treatment with a direct oral anticoagulant after atrial fibrillation-related stroke that minimizes the risk of a composite outcome of ischemic or hemorrhagic events. DESIGN, SETTING, AND PARTICIPANTS: This phase 2, pragmatic, response-adaptive randomized clinical trial was conducted between June 2017 and June 2023 at acute care hospitals in Texas and included patients who had a mild to moderate ischemic stroke (minimum lesion diameter of 1.5 cm) with atrial fibrillation and were prescribed a direct oral anticoagulant within 2 weeks from stroke onset. INTERVENTION: Within 3 to 4 days after atrial fibrillation-associated ischemic stroke, patients were randomized to a group for treatment start date (group 1 was day 3 or 4 after stoke onset; group 2 was day 6; group 3 was day 10; and group 4 was day 14) with a direct oral anticoagulant for secondary stroke prevention. MAIN OUTCOMES AND MEASURES: The composite primary outcome was an ischemic (stroke or systemic embolism) or hemorrhagic (symptomatic intracranial hemorrhage or major systemic hemorrhage) event observed within 30 days from the index stroke time of onset. Posterior probabilities were used to estimate which timing groups were optimal for treatment initiation and were recalculated at predefined intervals. The randomization allocations were adjusted to favor the groups with higher probabilities. RESULTS: The trial enrolled and randomized 200 patients (50% were female; the median age was 75 years [IQR, 65-81 years]; 17.5% were Asian, Black, or >1 race; 16.5% were Hispanic; the median National Institutes of Health Stroke Scale score was 6.5 [IQR, 4-14]; and the median lesion diameter was 3.1 cm [IQR, 2.0-4.4 cm]). No ischemic events were observed for group 1, 3 events were observed for group 2, 2 events were observed for group 3, and 2 events were observed for group 4. One hemorrhagic event was observed for group 1, 1 event was observed for group 2, 1 event was observed for group 3, and 0 events were observed for group 4. Group 1 had a posterior probability of 0.41 for being the optimal day for treatment initiation and it was 0.26 for group 2, 0.17 for group 3, and 0.15 for group 4. The use of response-adaptive randomization was feasible and favored groups with earlier initiation times for use of a direct oral anticoagulant. CONCLUSIONS AND RELEVANCE: A clearly superior day to initiate use of a direct oral anticoagulant for secondary stroke prevention in patients with atrial fibrillation was not identified, but the evidence suggests that initiating use of a direct oral anticoagulant earlier is better than at later times within the first 2 weeks after stroke onset. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03021928.

来源:JAMA Neurol,查看原文。版权归原作者所有。

引用

  1. Warach SJ, Davis LA, Lawrence P, et al. Optimal Delay Time to Initiate Anticoagulation After Ischemic Stroke in Atrial Fibrillation: A Pragmatic, Response-Adaptive Randomized Clinical Trial. JAMA Neurol. 2025. PMID: 40163159. doi:10.1001/jamaneurol.2025.0285

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。